Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 6/20 | 0.57 |
| ▸ | CTSV | O60911 | 4/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.50 |
| ▸ | PPIA | P62937 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9671326 | 0.90 | HPD (0.54) | HPDCTSVCTSLPTGER1MEN1 | |
| SCHEMBL30008122 | 0.89 | PTGER1 (0.64) | HPDCTSVCTSLPTGER1MEN1 | |
| SCHEMBL2991148 | 0.89 | HTT (0.53) | HPDCTSVCTSLMEN1KMT2A | |
| SCHEMBL30662860 | 0.88 | KMT2A (0.54) | HPDCTSVCTSLPTGER1MEN1 | |
| SCHEMBL26604443 | 0.88 | KMT2A (0.54) | HPDCTSVCTSLPTGER1MEN1 | |
| SCHEMBL15013285 | 0.88 | MAPT (0.55) | HPDMEN1KMT2AALDH1A1PPIA | |
| SCHEMBL21402679 | 0.85 | CTSV (0.53) | HPDCTSVCTSLPTGER1MEN1 | |
| SCHEMBL30318898 | 0.84 | HPD (0.49) | HPDMEN1KMT2AALDH1A1PPIA | |
| SCHEMBL1121791 | 0.84 | HPD (0.49) | HPDMEN1KMT2AALDH1A1PPIA | |
| SCHEMBL18949789 | 0.83 | MAOB (0.51) | HPDCTSVCTSLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-RE43481-E1 | Diazepan derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-7786106-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786106-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786106-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | ASTELLAS PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | ASTELLAS PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | ASTELLAS PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7504417-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504417-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-6642224-B1 | Diazepan derivatives or salts thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030195193-A1 | Diazepane derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1336605-A1 | SUBSTITUTED BENZENE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
| EP-1273575-A1 | DIAZEPANE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-08 | — | — | EP | disclosed |
| CN-1319594-A | Diazesuberane derivant or its salt | YAMANOUCHI PHARMA CO LTD (JP) | 2001-10-31 | — | — | CN | disclosed |
| US-6194396-B1 | ANTIALLERGENS; ANTIINFLAMMATION AGENTS; AUTOIMMUNE DISEASE; ANTISHOCK AGENTS; ANALGESICS; E.G., A 4 OR 7-PHENYLALKYLENE-OXYBENZIMIDAZOLE UNSUBSTITUTED OR SUBSTITUTED IN THE 1,2,3-POSITION WITH AN OXY, AMINO AND/OR THIO GROUP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| US-6083961-A | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0261503-B1 | HETEROCYCLIC AMIDO DERIVATIVES OF SUBSTITUTED BENZOIC ACIDS AND THERAPEUTIC COMPOSITIONS WHICH CONTAIN THEM AS ACTIVE PRINCIPLE | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1992-04-15 | — | — | EP | disclosed |
| EP-0261503-A1 | Heterocyclic amido derivatives of substituted benzoic acids and therapeutic compositions which contain them as active principle | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1988-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195193-A1 | Diazepane derivatives or salts thereof | F10, F11, SERPINC1 | HPD 461/4885CTSV 4780/4885CTSL 4003/4885 |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | PLG, MGAT3, F11 | HPD 285/4885CTSV 2780/4885CTSL 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.